Gracell Biotechnologies Inc. American Depositary Shares
GRCL
GRCL was delisted on the 21st of February, 2024.
36 hedge funds and large institutions have $123M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 4 closing their positions.
118% more capital invested
Capital invested by funds: $56.3M → $123M (+$66.5M)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
9% more funds holding
Funds holding: 33 → 36 (+3)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.02M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.04M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$2.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$632K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.17M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.48M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.42M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.49M |
| 5 |
O
OrbiMed
New York
|
-$1.3M |
GRCL Hedge Fund Activity: Q2 2023 in Review
36 institutional investors reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q2 2023, worth a combined $123M — up 118% from $56.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GRCL positions and 4 closed out — a net gain of 4 holders — while 12 added to existing stakes and 13 trimmed.
The largest buyer was Vivo Capital, adding an estimated $7.02M. The largest seller was Sphera Funds Management, cutting an estimated $3.17M.
- 36 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q2 2023, up from 33 in Q1 2023.
- Funds reported $123M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q2 2023, up 118% quarter-over-quarter.
- 8 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q2 2023 and 4 closed out, a net change of +4 holders.
- The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q2 2023 was Vivo Capital, an estimated $7.02M added.
- The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q2 2023 was Sphera Funds Management, an estimated $3.17M sold.
Based on aggregated 13F filings for Q2 2023.